Investor Relations

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put our financial performance into perspective.

Receptos team
- 1.26 (-0.73%)
Day High: 174.36 Day Low: 169.00 Volume: 496,200
4:00 PM ET on
Apr 24, 2015
Delayed at least 20 minutes.
Apr 16, 2015
Receptos Reports Positive Results for the Maintenance Period of the Phase 2 TOUCHSTONE Trial of Ozanimod in Ulcerative Colitis MORE»
Apr 1, 2015
Receptos Completes Enrollment of RADIANCE Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis MORE»
Mar 12, 2015 at 2:05 PM ET
Barclays Global Healthcare Conference MORE»
Mar 4, 2015
Interview with Faheem Hasnain, President and CEO, on Mad Money MORE»